RxDoctor Payments Data

Susan Coe, MD

Gastroenterology · Lawrenceville, GANPI 1609033315

Payments from drug & device makers

$5,617in general payments, 2019–2025

Across 307 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$578
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$557
  • Takeda Pharmaceuticals U.S.A., Inc.$433
  • Merck$324
  • Pfizer$288
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,51798%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,617 in reported general payments places this provider in the 60th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$189,664
Medicare patients
348
Services billed
5,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$579,977
Humira(Cf) PenAdalimumab31$327,250
XifaxanRifaximin42$134,973
CreonLipase/Protease/Amylase33$65,538
LinzessLinaclotide47$38,185
Mesalamine42$31,682
Dexlansoprazole DrDexlansoprazole35$12,843
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates82$5,848
Rabeprazole Sodium65$3,792
Budesonide DrBudesonide15$3,260
Lubiprostone23$2,761
Omeprazole202$2,276
Ondansetron Hcl49$1,043
Pantoprazole Sodium85$1,041
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl43$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$578$579,97721 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$557$134,97342 claims
AbbVieCreon, Linzess$1,585$103,72480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →